Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

Updated: December 9, 2024

Dunham Group broker earns key real estate trade designation

Three people stand in a line. File PHOTO / TIM GREENWAY Bryan Plourde of the Dunham Group, left, earned the MAI designation. Seen here earlier this year, he’s with Taylor Woodward and Matt Wheaton of DEW Construction Corp.

The Dunham Group announced that one of its brokers earned a key trade recognition from the Appraisal Institute.

Bryan Plourde earned the MAI designation (Member, Appraisal Institute). An MAI-designated appraiser has completed advanced coursework, passed rigorous examinations and met specific experience requirements in commercial property valuation. 

According to the institute, MAI-designated members agree to adhere to its code of professional ethics and standards of professional practice. The completion of continuing education requirements aims to ensure that MAI designated members remain informed on trends and changes pertaining to real property valuation, enabling them to provide valuations that reflect the latest in professional practice. 

The MAI designation has long been recognized by courts of law, government agencies, financial institutions and investors in the field of real estate valuation and analysis.

“Bryan is the only MAI designee active in commercial real estate brokerage in Maine,” said Justin Lamontagne, Dunham Group’s managing partner and designated broker. “He continues to differentiate his resume and skill set among his peers.”

Plourde joined the Dunham Group in 2023, having spent the last 11 years as a commercial real estate appraiser at Maine Valuation Co.

Plourde is a member of the New England CCIM (Certified Commercial Investment Member) chapter, a past committee member of the Maine Chapter of the Appraisal Institute, has his Member of the Appraisal Institute designation and is the education chair for the Maine Chapter of the Foundation Fighting Blindness, the world’s leading private funder of retinal disease research.

Sign up for Enews

Related Content

0 Comments

Order a PDF